Rosalie C Sears

List of Publications by Year
in descending order

81 papers	7,531 citations	76326 40 h-index	71685 76 g-index
82 all docs	82 docs citations	82 times ranked	10835 citing authors

#	Article	IF	Citations
1	A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biology, 2004, 6, 308-318.	10.3	687
2	CIP2A Inhibits PP2A in Human Malignancies. Cell, 2007, 130, 51-62.	28.9	662
3	FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to Î³-secretase inhibitors. Journal of Experimental Medicine, 2007, 204, 1813-1824.	8.5	605
4	Ras Enhances Myc Protein Stability. Molecular Cell, 1999, 3, 169-179.	9.7	413
5	MYC Degradation. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014365-a014365.	6.2	342
6	The Life Cycle of C-Myc: From Synthesis to Degradation. Cell Cycle, 2004, 3, 1131-1135.	2.6	318
7	Protein Phosphatase 2A Regulatory Subunit B56Î± Associates with c-Myc and Negatively Regulates c-Myc Accumulation. Molecular and Cellular Biology, 2006, 26, 2832-2844.	2.3	220
8	A Stromal Lysolipidâ€“Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. Cancer Discovery, 2019, 9, 617-627.	9.4	209
9	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	7.0	200
10	Direct interaction between the inhibitor 2 and ceramideviasphingolipidâ€protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB Journal, 2009, 23, 751-763.	0.5	189
11	Focal Adhesion Kinase Is Required for Intestinal Regeneration and Tumorigenesis Downstream of Wnt/c-Myc Signaling. Developmental Cell, 2010, 19, 259-269.	7.0	176
12	The life cycle of C-myc: from synthesis to degradation. Cell Cycle, 2004, 3, 1133-7.	2.6	173
13	Modeling Tumor Phenotypes InÂVitro with Three-Dimensional Bioprinting. Cell Reports, 2019, 26, 608-623.e6.	6.4	169
14	Inhibition of c-Myc activity by ribosomal protein L11. EMBO Journal, 2007, 26, 3332-3345.	7.8	168
15	Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9157-9162.	7.1	160
16	The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3734-3739.	7.1	160
17	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal of Clinical Investigation, 2017, 127, 2081-2090.	8.2	155
18	Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland. Cancer Research, 2011, 71, 925-936.	0.9	146

#	Article	IF	Citations
19	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2018, 34, 396-410.e8.	16.8	146
20	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nature Communications, 2018, 9, 3815.	12.8	137
21	Mission Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs, 2019, 33, 539-553.	4.6	113
22	Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clinical Cancer Research, 2014, 20, 2092-2103.	7.0	108
23	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. Journal of Clinical Oncology, 2018, 36, 2887-2894.	1.6	108
24	Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis. Molecular and Cellular Biology, 2013, 33, 2930-2949.	2.3	103
25	The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO Journal, 2009, 28, 500-512.	7.8	101
26	A tumor suppressor role for PP2A-B56Î± through negative regulation of c-Myc and other key oncoproteins. Cancer and Metastasis Reviews, 2008, 27, 147-158.	5.9	97
27	Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer. Molecular Cancer Research, 2014, 12, 924-939.	3.4	89
28	MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 2017, 8, 1728.	12.8	83
29	AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 2021, 592, 799-803.	27.8	78
30	Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology, 2021, 17, 954-963.	8.0	73
31	Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2790-2795.	7.1	69
32	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 2065-2080.	0.9	60
33	Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Cancer Letters, 2020, 492, 63-70.	7.2	60
34	SUMO protease SENP1 deSUMOylates and stabilizes c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10983-10988.	7.1	59
35	Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 209-219.	0.9	56
36	Feedback Regulation of c-Myc by Ribosomal Protein L11. Cell Cycle, 2007, 6, 2735-2741.	2.6	55

#	Article	IF	Citations
37	Writing and erasing MYC ubiquitination and SUMOylation. Genes and Diseases, 2019, 6, 359-371.	3.4	55
38	Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes and Development, 2018, 32, 1398-1419.	5.9	52
39	Inhibition of 5-Lipoxygenase Selectively Triggers Disruption of c-Myc Signaling in Prostate Cancer Cells. Journal of Biological Chemistry, 2015, 290, 4994-5006.	3.4	50
40	Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation. Cell Reports, 2015, 12, 1019-1031.	6.4	50
41	Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity. Structure, 2015, 23, 2267-2279.	3.3	48
42	High-content single-cell combinatorial indexing. Nature Biotechnology, 2021, 39, 1574-1580.	17.5	39
43	A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19685-19690.	7.1	34
44	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. Journal of Biological Chemistry, 2020, 295, 757-770.	3.4	34
45	Deubiquitinating c-Myc: USP36 steps up in the nucleolus. Cell Cycle, 2015, 14, 3786-3793.	2.6	31
46	Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. Journal of Clinical Investigation, 2019, 130, 231-246.	8.2	31
47	Loss of Ambra1 promotes melanoma growth and invasion. Nature Communications, 2021, 12, 2550.	12.8	30
48	Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	26
49	Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 84214-84227.	1.8	26
50	The ubiquitin-specific protease USP36 is a conserved histone H2B deubiquitinase. Biochemical and Biophysical Research Communications, 2018, 495, 2363-2368.	2.1	24
51	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. Journal of Biological Chemistry, 2020, 295, 757-770.	3.4	24
52	Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy. Frontiers in Oncology, 2021, 11, 679445.	2.8	20
53	Innate Î±Î² T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. Cancer Discovery, 2019, 9, 1288-1305.	9.4	19
54	Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer. PLoS Computational Biology, 2019, 15, e1006840.	3.2	18

#	Article	IF	Citations
55	The tumor suppressor phosphatase PP2A-B56Î± regulates stemness and promotes the initiation of malignancies in a novel murine model. PLoS ONE, 2017, 12, e0188910.	2.5	17
56	The deubiquitinase USP36 promotes snoRNP group SUMOylation and is essential for ribosome biogenesis. EMBO Reports, 2021, 22, e50684.	4.5	17
57	Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Cancer Discovery, 2017, 7, 131-133.	9.4	16
58	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.9	15
59	Î”N-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival. Biochemical and Biophysical Research Communications, 2017, 482, 1271-1277.	2.1	12
60	GRB7 dependent proliferation of basalâ€like, HERâ€2 positive human breast cancer cell lines is mediated in part by HERâ€1 signaling. Molecular Carcinogenesis, 2019, 58, 699-707.	2.7	9
61	Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. Annual Review of Cancer Biology, 2021, 5, 39-57.	4.5	9
62	A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations. , 2016, , .		8
63	Altering MYC phosphorylation in the epidermis increases the stem cell population and contributes to the development, progression, and metastasis of squamous cell carcinoma. Oncogenesis, 2020, 9, 79.	4.9	8
64	Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer. Trends in Pharmacological Sciences, 2020, 41, 595-597.	8.7	7
65	PIN1 Provides Dynamic Control of MYC in Response to Extrinsic Signals. Frontiers in Cell and Developmental Biology, 2020, 8, 224.	3.7	7
66	Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity. Blood, 2012, 119, 5334-5335.	1.4	6
67	On the Analysis of Cyclic Drug Schedules for Cancer Treatment using Switched Dynamical Systems. , 2018, , .		6
68	Detection of Post-translational Modifications on MYC. Methods in Molecular Biology, 2021, 2318, 69-85.	0.9	6
69	The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Molecular and Cellular Biology, 2022, 42, .	2.3	6
70	Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Pharmaceutics, 2022, 14, 713.	4.5	5
71	Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC. Cancer Discovery, 2020, 10, 495-497.	9.4	4
72	HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Cancers, 2022, 14, 1848.	3.7	4

#	Article	IF	Citations
73	Detection of c-Myc Proteinâ€“Protein Interactions and Phosphorylation Status by Immunoprecipitation. Methods in Molecular Biology, 2013, 1012, 65-76.	0.9	3
74	Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. JCO Precision Oncology, 2021, 5, 344-356.	3.0	2
75	AB024. S024. Drug responses of patient-derived cell lines in vitro that match drug responses of patient PDAc tumors in situ. Annals of Pancreatic Cancer, 2018, 1, AB024-AB024.	1.2	2
76	Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Cancer Research, 2022, 82, 3375-3393.	0.9	2
77	The use of protein phosphatase 2A activators in combination therapies for pancreas cancer. Oncotarget, 2019, 10, 2008-2009.	1.8	1
78	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. Cancer & Metabolism, 2021, 9, 31.	5.0	1
79	The Prolyl Isomerase PIN1 Plays a Critical Role in Fibroblast Differentiation States to Support Pancreatic Cancer. SSRN Electronic Journal, 0, , .	0.4	0
80	Aberrant Stabilization of c-Myc Protein in Lymphoblastic and Myelogenous Leukemia Cell Lines.. Blood, 2004, 104, 1532-1532.	1.4	0
81	T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62. Molecular Cancer Research, 2022, 20, 1151-1165.	3.4	0